Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Widespread intra-axonal signal fraction abnormalities in bipolar disorder from multicompartment diffusion, Sensitivity to diagnosis, association with clinical features and pharmacologic treatment

  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Verdolini, Norma|||0000-0001-9488-2881
  • Alonso-Lana, Silvia|||0000-0002-3063-6929
  • Torres, María Llanos
  • Panicalli, Francesco
  • Argila-Plaza, Isabel|||0000-0002-1604-4708
  • Rodriguez-Cano, Elena
  • Montoro, Irene
  • Garcia-Ruiz, Beatriz
  • Jimenez, Esther|||0000-0001-6929-6207
  • Varo, Cristina|||0000-0002-8859-3052
  • Lluch, Anna
  • del Mar Bonnin, Caterina
  • Maluf, Silvana
  • Pujol, Marc
  • Jaurrieta Guarner, Núria
  • Sarró, Salvador|||0000-0003-1835-2189
  • Vieta, Eduard|||0000-0002-0548-0053
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Salvador, Raymond|||0000-0001-5557-1562
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
Despite diffusion tensor imaging (DTI) evidence for widespread fractional anisotropy (FA) reductions in the brain white matter of patients with bipolar disorder, questions remain regarding the specificity and sensitivity of FA abnormalities as opposed to other diffusion metrics in the disorder. We conducted a whole-brain voxel-based multicompartment diffusion MRI study on 316 participants (i.e., 158 patients and 158 matched healthy controls) employing four diffusion metrics: the mean diffusivity (MD) and FA estimated from DTI, and the intra-axonal signal fraction (IASF) and microscopic axonal parallel diffusivity (Dpar) derived from the spherical mean technique. Our findings provide novel evidence about widespread abnormalities in other diffusion metrics in BD. An extensive overlap between the FA and IASF results suggests that the lower FA in patients may be caused by a reduced intra-axonal volume fraction or a higher macromolecular content in the intra-axonal water. We also found a diffuse alteration in MD involving white and grey matter tissue and more localised changes in Dpar. A Machine Learning analysis revealed that FA, followed by IASF, were the most helpful metric for the automatic diagnosis of BD patients, reaching an accuracy of 72%. Number of mood episodes, age of onset/duration of illness, psychotic symptoms, and current treatment with lithium, antipsychotics, antidepressants, and antiepileptics were all significantly associated with microstructure abnormalities. Lithium treatment was associated with less microstructure abnormality. A whole-brain voxel-based approach combining DTI and SMT diffusion-derived metrics to reveal specific brain tissue microstructure abnormalities in bipolar disorder (BD) was carried out. We also evaluate the sensitivity of various diffusion metrics for the automatic diagnosis of BD through machine learning algorithms and cross-validation. Finally, we look for differences between BD subtypes and the possible effect of duration of illness, age at onset, history of psychosis, and pharmacological treatment with lithium, antidepressant, antipsychotic, and antiepileptic drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands

  • Díaz-Tejedor, A.
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Lorenzo-Mohamed, M.
  • González-Rodríguez, M.
  • Castellanos, B.
  • Sotolongo-Ravelo, J.
  • San-Segundo, L.
  • Corchete, L.A.
  • González-Méndez, L.
  • Martín Sánchez, Montserrat
  • Mateos, M. V.|||0000-0003-2390-1218
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Garayoa, M.
  • Paíno, T.
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients' samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Human Wharton's jelly-derived mesenchymal stromal cells promote bone formation in immunodeficient mice when administered into a bone microenvironment

  • Cabrera-Pérez, Raquel|||0000-0002-4858-0142
  • Ràfols-Mitjans, Alexis
  • Roig-Molina, Ángela
  • Beltramone, Silvia
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Batlle Morera, Laura|||0000-0002-6924-9002
Wharton's Jelly (WJ) Mesenchymal Stromal Cells (MSC) have emerged as an attractive allogeneic therapy for a number of indications, except for bone-related conditions requiring new tissue formation. This may be explained by the apparent recalcitrance of MSC,WJ to differentiate into the osteogenic lineage in vitro, as opposed to permissive bone marrow (BM)-derived MSCs (MSC,BM) that readily commit to bone cells. Consequently, the actual osteogenic in vivo capacity of MSC,WJ is under discussion. We investigated how physiological bone environments affect the osteogenic commitment of recalcitrant MSCs in vitro and in vivo. To this end, MSC of BM and WJ origin were co-cultured and induced for synchronous osteogenic differentiation in vitro using transwells. For in vivo experiments, immunodeficient mice were injected intratibially with a single dose of human MSC and bone formation was evaluated after six weeks. Co-culture of MSC,BM and MSC,WJ resulted in efficient osteogenesis in both cell types after three weeks. However, MSC,WJ failed to commit to bone cells in the absence of MSC,BM's osteogenic stimuli. In vivo studies showed successful bone formation within the medullar cavity of tibias in 62.5% of mice treated with MSC, WJ. By contrast, new formed trabeculae were only observed in 25% of MSC,BM-treated mice. Immunohistochemical staining of human COXIV revealed the persistence of the infused cells at the site of injection. Additionally, cells of human origin were also identified in the brain, heart, spleen, kidney and gonads in some animals treated with engineered MSC,WJ (eMSC,WJ). Importantly, no macroscopic histopathological alterations, ectopic bone formation or any other adverse events were detected in MSC-treated mice. Our findings demonstrate that in physiological bone microenvironment, osteogenic commitment of MSC,WJ is comparable to that of MSC,BM, and support the use of off-the-shelf allogeneic MSC,WJ products in bone repair and bone regeneration applications. The online version contains supplementary material available at 10.1186/s12967-023-04672-9.
Repisalud
Publicación Artículo científico (JournalArticle)

Sustained antiviral response against HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib

  • Manzanares, Mario
  • Ramos-Martín, Fernando
  • Rodriguez Mora, Sara
  • Casado-Fernández, Guiomar
  • Sánchez-Menéndez, Clara
  • Simón-Rueda, Alicia
  • Mateos, Elena
  • Cervero, Miguel
  • Spivak, Adam M
  • Planelles, Vicente
  • Torres, Montserrat
  • García-Gutiérrez, Valentín
  • Coiras, Mayte
HIV-1 infection cannot be cured due to long-lived viral reservoirs formed by latently infected CD4 T cells. "Shock and Kill" strategy has been considered to eliminate the viral reservoir and achieve a functional cure but the stimulation of cytotoxic immunity is necessary. Ponatinib is a tyrosine kinase inhibitor (TKI) clinically used against chronic myeloid leukemia (CML) that has demonstrated to be effective against HIV-1 infection . Several TKIs may induce a potent cytotoxic response against cancer cells that makes possible to discontinue treatment in people with CML who present long-term deep molecular response. In this longitudinal study, we analyzed the capacity of ponatinib to induce an antiviral response against HIV-1 infection in peripheral blood mononuclear cells (PBMCs) obtained from people with CML previously treated with imatinib for a median of 10 years who changed to ponatinib for 12 months to boost the anticancer response before discontinuing any TKI as part of the clinical trial NCT04043676. Participants were followed-up for an additional 12 months in the absence of treatment. PBMCs were obtained at different time points and then infected with HIV-1. The rate of infection was determined by quantifying the intracellular levels of p24-gag in CD4 T cells. The levels of p24-gag+ CD4 T-cells were lower when these cells were obtained during and after treatment with ponatinib in comparison with those obtained during treatment with imatinib. Cytotoxicity of PBMCs against HIV-infected target cells was significantly higher during treatment with ponatinib than during treatment with imatinib, and it was maintained at least 12 months after discontinuation. There was a significant negative correlation between the lower levels of p24-gag+ CD4 T-cells and the higher cytotoxicity induced by PBMCs when cells were obtained during and after treatment with ponatinib. This cytotoxic immunity was mostly based on higher levels of Natural Killer and Tγδ cells seemingly boosted by ponatinib. In conclusion, transient treatment with immunomodulators like ponatinib along with ART could be explored to boost the antiviral activity of cytotoxic cells and contribute to the elimination of HIV-1 reservoir.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Brain imaging correlates of self- and other-reflection in schizophrenia

  • Fuentes-Claramonte, Paola|||0000-0002-1428-7976
  • Martin-Subero, Marta|||0000-0003-2053-976X
  • Salgado-Pineda, Pilar|||0000-0001-7720-0885
  • Santo-Angles, Aniol
  • Argila-Plaza, Isabel|||0000-0002-1604-4708
  • Salavert, Josep
  • Arévalo, Antoni
  • Bosque, Clara
  • Sarri, Carmen
  • Guerrero-Pedraza, Amalia|||0000-0001-7567-9407
  • Capdevila, Antoni
  • Sarró, Salvador|||0000-0003-1835-2189
  • McKenna, Peter J.
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Salvador, Raymond|||0000-0001-5557-1562
An alteration in self/other differentiation has been proposed as a basis for several symptoms in schizophrenia, including delusions of reference and social functioning deficits. Dysfunction of the right temporo-parietal junction (TPJ), a region linked with social cognition, has been proposed as the basis of this alteration. However, imaging studies of self- and other-processing in schizophrenia have shown, so far, inconsistent results. Patients with schizophrenia and healthy controls underwent fMRI scanning while performing a task with three conditions: self-reflection, other-reflection and semantic processing. Both groups activated similar brain regions for self- and other-reflection compared to semantic processing, including the medial prefrontal cortex, the precuneus and the TPJ. Compared to healthy subjects, patients hyperactivated the left lateral frontal cortex during self- and other-reflection. In other-reflection, compared to self-reflection, patients failed to increase right TPJ activity. Altered activity in the right TPJ supports a disturbance in self/other differentiation in schizophrenia, which could be linked with psychotic symptoms and affect social functioning in patients. Hyperactivity of the lateral frontal cortex for self- and other-reflection suggests the presence of greater cognitive demand to perform the task in the patient group.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Autobiographical memory and default mode network function in schizophrenia, an fMRI study

  • Martin-Subero, Marta|||0000-0003-2053-976X
  • Fuentes-Claramonte, Paola|||0000-0002-1428-7976
  • Salgado-Pineda, Pilar|||0000-0001-7720-0885
  • Salavert, Josep
  • Arévalo, Antoni
  • Bosque, Clara
  • Sarri, Carmen
  • Guerrero-Pedraza, Amalia|||0000-0001-7567-9407
  • Santo-Angles, Aniol
  • Capdevila, Antoni
  • Sarró, Salvador|||0000-0003-1835-2189
  • Salvador, Raymond|||0000-0001-5557-1562
  • McKenna, Peter J.
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
The brain functional correlates of autobiographical recall are well established, but have been little studied in schizophrenia. Additionally, autobiographical memory is one of a small number of cognitive tasks that activates rather than de-activates the default mode network, which has been found to be dysfunctional in this disorder. Twenty-seven schizophrenic patients and 30 healthy controls underwent functional magnetic resonance imaging while viewing cue words that evoked autobiographical memories. Control conditions included both non-memory-evoking cues and a low level baseline (cross fixation). Compared to both non-memory evoking cues and low level baseline, autobiographical recall was associated with activation in default mode network regions in the controls including the medial frontal cortex, the posterior cingulate cortex and the hippocampus, as well as other areas. Clusters of de-activation were seen outside the default mode network. There were no activation differences between the schizophrenic patients and the controls, but the patients showed clusters of failure of de-activation in non-default mode network regions. According to this study, patients with schizophrenia show intact activation of the default mode network and other regions associated with recall of autobiographical memories. The finding of failure of de-activation outside the network suggests that schizophrenia may be associated with a general difficulty in de-activation rather than dysfunction of the default mode network per se.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment of non-hypertrophic pseudoarthrosis of long bones with a Tissue Engineered Product loaded with autologous bone marrow-derived Mesenchymal Stromal Cells, Results from a phase IIa, prospective, randomized, parallel, pilot clinical trial comparing to iliac crest autograft

  • Chaverri, Daniel
  • Gallardo-Villares, Santiago
  • Pinto, Javier A.
  • Rodríguez, Luciano
  • Codinach, Margarita|||0000-0003-0560-8798
  • García López, Joan
  • Querol, Sergi|||0000-0002-1105-8633
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Granell-Escobar, Fernando
Background: Atrophic pseudoarthrosis is a serious complication with an incidence of 5-10 % of bone fractures located in the diaphysis of long bones. Standard treatments involve aggressive surgical procedures and re-interventions requiring the use of autografts from the iliac crest as a source of bone-forming biological activity (Standard of Care, SoC). In this context, regenerative ex vivo expanded osteogenic cell-based medicines could be of interest. Particularly, Mesenchymal Stromal Cells (MSC) offer new prospects to promote bone tissue repair in pseudoarthrosis by providing biological activity in an osteoconductive and osteoinductive environment. Methods: We conducted a phase IIa, prospective, randomised, parallel, two-arms, open-label with blinded assessor pilot clinical trial to compare SoC vs. a tissue-engineered product (TEP), composed of autologous bone marrow (BM)-derived MSCs loaded onto allogeneic decellularised, lyophilised spongy bone cubes, in a cohort of 20 patients with non-hypertrophic pseudoarthrosis of long bones. Patients were followed up for 12 months. Radiological bone healing was evaluated by standard X-ray and computed tomography (CT) scanning. Quality of life was measured using the EUROQOL-5D questionnaire. Results: Ten patients were randomized to TEP and 10 to SoC with iliac crest autograft. Manufacturing of TEP was feasible and reproducibly achieved. TEP implantation in the bone defect was successful in all cases and none of the 36 adverse events (AE) reported were related to the treatment. Efficacy analyses were performed in the Full Analysis Set (FAS) population, which included 17 patients after 3 patients withdrew from the study. The degree of consolidation, estimated by measuring Hounsfield units (HU) on CT, showed no significant differences between the two treatment groups at 12 months post treatment (main efficacy variable) (p = 0.4835) or at 6 months. Conclusions: Although only a small number of patients were included in our study, it is notable that no significant differences were observed between the experimental treatment and SoC, thus suggesting TEP as an alternative where autograft is not available or contraindicated.